Fedratinib Production Cost Reports

The report provides a detailed analysis essential for establishing a Fedratinib production plant. It encompasses all critical aspects necessary for Fedratinib production, including the cost of Fedratinib production, Fedratinib plant cost, Fedratinib production costs, and the overall Fedratinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Fedratinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Fedratinib is a small-molecule pharmaceutical compound that is primarily used in the treatment of certain blood-related disorders. It is primarily prescribed for patients with myeloproliferative neoplasms, especially myelofibrosis, where it helps reduce disease-related symptoms and spleen enlargement by targeting abnormal cell signalling pathways. It plays an important role in managing patients who do not respond well to other therapies, improving their quality of life. It is mainly used in the treatment of patients with myelofibrosis after polycythemia vera or essential thrombocythemia, often after prior JAK inhibitor use. It is also used in clinical research to study targeted cancer therapies and disease mechanisms.

The demand for fedratinib is mainly driven by its application as an oral kinase inhibitor medication in haematology-oncology for blood cancers, which fuels its market expansion. Its application in the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis in adults significantly promotes its demand in the medical sector. Its application as a second-line therapy to manage disease-related splenomegaly and constitutional symptoms in JAK-naïve cases also strengthens its demand in the oncology sector. Its demand as a valuable drug in modern haematology and oncology for specialised cancer treatment also contributes to its market growth.

Additionally, its use in managing symptoms such as anaemia, fatigue, and splenomegaly in myelofibrosis patients further fuels its demand in the healthcare and pharmaceutical industries. Industrial fedratinib procurement depends on factors including the cost and availability of raw materials, regulatory approvals, and adherence to stringent safety and environmental guidelines. Furthermore, advancements in drug synthesis technologies, reliable supplier networks, quality control practices, and efficient logistics play a significant role in shaping its global procurement strategies.

Raw Material for Fedratinib Production

According to the Fedratinib production plant project report, the major raw materials for Fedratinib production include Pyrimidine, 3-bromo-N-(tert-butyl)benzenesulfonamide, and 4-(2-(pyrrolidin-1-yl)ethoxy)aniline.

Production Process of Fedratinib

The extensive Fedratinib production cost report consists of the following industrial production process:

1. Production via Coupling Reaction: The production process of fedratinib begins with a metal-catalysed coupling reaction between pyrimidine and 3-bromo-N-(tert-butyl)benzenesulfonamide, using Pd2(dba)3 and Xantphos as catalysts to form an intermediate compound, 3-((2-chloro-5-methylpyrimidin-4-yl)amino)-N-(tert-butyl)benzenesulfonamide. Then, this intermediate undergoes a microwave-assisted SNAr reaction with 4-(2-(pyrrolidin-1-yl)ethoxy)aniline under acid-mediated conditions, which results in the formation of fedratinib as the final product.

Fedratinib is a selective inhibitor of Janus kinase 2 used in the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis. It appears as a white to off-white solid powder with an odourless or faint characteristic odour. The molecular formula of the compound is C27H36N6O3S, and its molecular mass is 524.68 g/mol. It has a density of approximately 1.2 g/cm³, and the compound has a boiling point of around 713.7 degree Celsius at 760 mmHg. The flash point of the compound is around 385.5 degree Celsius. It is practically insoluble in water but readily soluble in organic solvents such as dimethyl sulfoxide and requires storage at -20 degree Celsius, in a dry and dark environment to maintain stability. Its melting point is around 180-182 degree Celsius. The compound is administered orally as fedratinib hydrochloride capsules and shows high lipophilicity with a LogP value of 3.27.  It is recommended to handle the compound with appropriate personal protective equipment in a well-ventilated area. Extended exposure or improper use may lead to adverse effects, including anaemia, thrombocytopenia, gastrointestinal toxicity, and hepatic complications.